Erlotinib plus bevacizumab

DRUG2 trials

Sponsors

Shizuoka cancer center, National Cancer Center, Korea

Conditions

EGFR Positive Non-small Cell Lung CancerNon-small cell lung cancer

Phase 2

A phase II study of erlotinib plus bevacizumab in patients with performance status 2 to 3 and EGFR mutation-positive advanced non-small-cell lung cancer

Active, not recruitingJPRN-UMIN000016507

Shizuoka cancer centerNon-small cell lung cancer

Start: 2015-02-10Target: 21Updated: 2026-06-29

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

National Cancer Center, KoreaEGFR Positive Non-small Cell Lung Cancer

Start: 2016-11-01End: 2023-07-20Target: 128Updated: 2022-04-06

Related Papers

A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non–small cell lung cancer (NSCLC) with <i>EGFR</i> mutation.

Journal of Clinical Oncology2022-06-01